alexa Development Of An Immuno-suppressive Agent, Cyn-1324 For Treating With Asthma
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

6th World Pharmacists and Clinical Pharmacy Annual Congress
May 22-23, 2017 Chicago, USA

Hueih-Min Chen
National Nano Device Laboratories, Taiwan
Posters & Accepted Abstracts: J Clin Trials
DOI: 10.4172/2167-0870-C1-014
Abstract
Cyn-1324 (C18H25NO5; MW: 335 g/mol; patents: ROC/I481600; USA/9,126,968; China/in pending) is a derivative of Cynarin (Cyn) which was found by using chip-based innovative screening method. A simple protocol for synthesis of Cyn-1324 has been established and satisfied with the regulation of chemical-manufacture-control (CMC). Molecular-based computer simulation of the association between Cyn-1324 and CD28 shows that the minimum energy is about - 8.59 kcal/mol which is the smallest energy minimization as compared with that of the association between CD28 and CD80. This implies that Cyn- 1324 can exclude CD80 to bind with CD28. The cross validation for identifying the blocking effect of Cyn-1324 on CD28 was done on: (1) Protein-protein level: CD28-Cyn-1324-CD80; (2) Cell-protein level: T-cell (including CD28)-Cyn-1324-CD80; (3) Cell-cell level: T-cell (including CD28)-Cyn-1324-Bcell (including CD80). Their binding forces are measured by atomic force microscopy (AFM) showing the blocking effect of 30.5%, 41.25 and 19.0% for protein-protein, cell-protein and cell-cell levels, respectively. Toxicity test of animal model using Cyn-1324 (5 repeated doses, 50 mg/kg per time) verified that there has no toxicity on organs (spleen, liver and kidney) of BALB/c mice. The disease-model (asthma) test, via intra-peritoneal injection, further shows that Cyn-1324 could suppress airway hyper-responsiveness and eosinophil infiltration of the lung in OVA-sensitized mice. Further experiments will be done in detail about the possible treatment of Cyn-1324 on asthma disease.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords